Susquehanna Fundamental Investments LLC Makes New Investment in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Susquehanna Fundamental Investments LLC acquired a new position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 123,769 shares of the company's stock, valued at approximately $922,000. Susquehanna Fundamental Investments LLC owned approximately 0.18% of EyePoint Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in EYPT. Barclays PLC boosted its stake in EyePoint Pharmaceuticals by 410.4% during the 3rd quarter. Barclays PLC now owns 245,045 shares of the company's stock valued at $1,959,000 after purchasing an additional 197,033 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in EyePoint Pharmaceuticals by 1,171.3% during the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock valued at $2,970,000 after buying an additional 342,516 shares in the last quarter. Franklin Resources Inc. boosted its stake in EyePoint Pharmaceuticals by 9.9% during the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after buying an additional 362,399 shares in the last quarter. abrdn plc bought a new stake in EyePoint Pharmaceuticals in the fourth quarter worth about $1,719,000. Finally, Rhumbline Advisers lifted its holdings in EyePoint Pharmaceuticals by 16.1% in the 4th quarter. Rhumbline Advisers now owns 89,560 shares of the company's stock valued at $667,000 after acquiring an additional 12,443 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on EYPT shares. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. StockNews.com upgraded EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 target price for the company. Finally, Chardan Capital reissued a "buy" rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $26.63.

EyePoint Pharmaceuticals Trading Down 9.0 %

NASDAQ EYPT traded down $0.62 during trading on Tuesday, reaching $6.24. The company's stock had a trading volume of 696,748 shares, compared to its average volume of 877,160. The stock has a market capitalization of $429.38 million, a PE ratio of -3.12 and a beta of 1.58. EyePoint Pharmaceuticals, Inc. has a 1-year low of $3.91 and a 1-year high of $14.00. The business has a 50-day moving average price of $6.02 and a 200-day moving average price of $7.60.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The business had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. As a group, analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.